Navigation Links
VIA Pharmaceuticals Set to Join Russell Microcap Index
Date:6/27/2008

ome cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

-- our ability to obtain necessary financing;

-- our ability to control our operating expenses;

-- our ability to recruit and enroll patients for the FDG-PET clinical

trial;

-- failure to obtain sufficient data from enrolled patients that can be

used to evaluate VIA-2291, thereby impairing the validity or

statistical significance of our clinical trials;

-- our ability to successfully complete our clinical trials of VIA-2291 on

expected timetables and the outcomes of such clinical trials;

-- complexities in designing and implementing cardiovascular clinical

trials using histological examinations, measurement of biomarkers,

medical imaging and atherosclerotic plaque bioassays;

-- the results of our clinical trials, including without limitation, with

respect to the safety and efficacy of VIA-2291;

-- the outcome of any legal proceedings;

-- our ability to obtain necessary FDA approvals;

-- our ability to successfully commercialize VIA-2291;

-- our ability to obtain and protect our intellectual property related to

our product candidates;

-- our potential for future growth and the development of our product

pipeline;

-- our ability to form and maintain collaborative relationships to develop

and commercialize our product candidates;

-- general economic and business conditions; and

-- the other risks described under Item IA "Risk Factors" in our Annual

Report on Form 10-K for the fiscal year ended December 31, 2007 on file

with the SEC.

All forward-looking statements attributable to us or persons acting on our be
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Wyeth Pharmaceuticals Announces Organizational Change
2. Access Pharmaceuticals Presents New Data at International Symposium Showing Companys Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
3. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
4. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
5. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
6. Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals
7. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
8. Onyx Pharmaceuticals to Present at Jefferies 2nd Annual Healthcare Conference
9. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
10. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
11. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014 /PRNewswire-iReach/ -- Researchers found that ... identifies patients with bone fragility fracture when today,s ... people worldwide are at risk of fracture for ... bone strength test, the DEXA bone density scan. ... for Bone and Mineral Research Annual Conference (ASBMR) ...
(Date:9/16/2014)... Canada (PRWEB) September 16, 2014 According ... the Toronto affiliate of ITRA Global, new development in ... the Toronto city council approving another 755 storeys of ... it appears construction cranes will be dominating the Toronto ... seems to have an unquenchable thirst for new development. ...
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... patient has sepsis, a life-threatening condition in which bacteria ... too fast for antibiotics to help. A new device ... team at Harvard,s Wyss Institute for Biologically Inspired Engineering ... , "Even with the best current treatments, sepsis patients ... percent of the time," said Mike Super, Ph.D., Senior ...
Breaking Biology Technology:ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 2ActiveLife's BMSi Test Provides Hope for 160 Million with Undetectable Risk of Bone Fracture 3ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4
... 2011 BioSpecifics Technologies Corp. (Nasdaq: BSTC ... products, today announced that BioSpecifics, President, Tom Wegman, will ... Health Care Conference on Monday, March 7, 2011, at ... Boston, Massachusetts. A live webcast of the ...
... Novavax, Inc. (Nasdaq: NVAX ) announced today ... company,s headquarters in Rockville, Maryland, on Monday, March 7, ... to $179 million. The Office of Biomedical Advanced Research ... Assistant Secretary for Preparedness and Response at the U.S. ...
... New research from the University of Pennsylvania demonstrates a ... atomic-scale material that has promising applications in a variety ... Nobel Prize in Physics. As explained in a ... to create high-quality graphene that is just a single ...
Cached Biology Technology:Maryland Governor Martin O'Malley to Visit Novavax in Celebration of HHS-BARDA Contract Award 2Maryland Governor Martin O'Malley to Visit Novavax in Celebration of HHS-BARDA Contract Award 3Maryland Governor Martin O'Malley to Visit Novavax in Celebration of HHS-BARDA Contract Award 4Penn physicists develop scalable method for making graphene 2Penn physicists develop scalable method for making graphene 3
(Date:9/16/2014)... show its extravagant, colorful tail feathers in courtship of ... a special camera developed by an engineer at Washington ... swordtail fish choose their mates based on a similar ... at Austin used a bioinspired polarization camera developed by ... engineering at Washington University, to make the discovery. His ...
(Date:9/16/2014)... waters of Southeast Alaska to the white sand beaches ... and tourist towns, coastal residents around the U.S. share ... along political lines. That,s a primary finding of a ... this month in the journal Society & Natural ... differences from place to place to place. Each environment ...
(Date:9/16/2014)... ethical choices such as buying clothing not made in ... and bringing their own bags when they go shopping? ... of Consumer Research , ethical consumption is motivated by ... unethical practices into action. , "Advocates of ethical consumerism ... costs of the products they choose, but unfortunately only ...
Breaking Biology News(10 mins):Camera developed at WUSTL sheds light on mate choice of swordtail fish 2Politics divide coastal residents' views of environment, UNH research finds 2Politics divide coastal residents' views of environment, UNH research finds 3Why are consumers willing to spend more money on ethical products? 2
... land managers on the Olympic Peninsula joined in an ... the University of Washington to develop a set of ... for resiliency and sustainability in the face of a ... of vegetation, hydrology, roads, fish, and wildlife on the ...
... In the chemistry of the living world, a pair of ... genetic code, they provide all organisms with a mechanism for ... vital to living systems. Yet according to John ... Informatics, at Arizona State University,s Biodesign Institute, it may not ...
... databases is just the tip of the iceberg in online ... focus to social networks and today a number of Facebook ... and other armed groups that have been included in the ... in a new study conducted by Prof. Gabriel Weimann of ...
Cached Biology News:Partnership yields options for adapting to climate change on the Olympic Peninsula 2Simpler times: Did an earlier genetic molecule predate DNA and RNA? 2Simpler times: Did an earlier genetic molecule predate DNA and RNA? 3Simpler times: Did an earlier genetic molecule predate DNA and RNA? 4A 'friend' request from al-Qaida 2
Mouse monoclonal [0.N.305] to G protein alpha - BSA and Azide free ( Abpromise for all tested applications). Antigen: Partially purified G protein alpha from rat brain. Entrez GeneID: 2778 ...
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
...
Guanine nucleotide-binding protein G(k), alpha subunit...
Biology Products: